Drug intelligence / Profile preview

ropivacaine + ketamine

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Perineural, Epidural, Caudal

Overview

A combination of ropivacaine, an amide-type local anesthetic, and ketamine, an NMDA receptor antagonist. This combination is used for regional anesthesia and pain management, particularly in nerve blocks. Ropivacaine blocks sodium channels to prevent nerve impulse generation and conduction, while ketamine provides additional analgesia through NMDA receptor antagonism. The combination has shown enhanced analgesic efficacy and prolonged duration of action in certain applications compared to either agent alone.

Other names: local anesthetic-ketamineropivacaine-ketamine combination

Targets

NaV (Voltage-gated sodium channels)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ropivacaine + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ropivacaine + ketamine.

Explore the full profile